MX9708043A - Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior. - Google Patents

Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.

Info

Publication number
MX9708043A
MX9708043A MX9708043A MX9708043A MX9708043A MX 9708043 A MX9708043 A MX 9708043A MX 9708043 A MX9708043 A MX 9708043A MX 9708043 A MX9708043 A MX 9708043A MX 9708043 A MX9708043 A MX 9708043A
Authority
MX
Mexico
Prior art keywords
miotic
anterior chamber
compositions
controlled release
mydriatic
Prior art date
Application number
MX9708043A
Other languages
English (en)
Inventor
Miles A Galin
Joseph C Salamone
Stanley C Israel
Original Assignee
Miles A Galin
Joseph C Salamone
Stanley C Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles A Galin, Joseph C Salamone, Stanley C Israel filed Critical Miles A Galin
Publication of MX9708043A publication Critical patent/MX9708043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a las composiciones que mantienen la integridad estructural de la cámara anterior del ojo durante la cirugía oftalmologica, protegiendo de esta manera los tejidos que forman y alinean el segmento anterior del daño potencial y proporcionar simultáneamente el suministro de un agente miotico y agente midriático. La presente invencion proporciona composiciones que comprenden un polímero viscoelástico, en donde la liberacion sostenida de un agente miotico o midriático es mediado por interacciones ionicas, así como composiciones en donde la liberacion sostenida de un agente miotico o midriático es mediada por microcápsulas o micelas de copolímero.
MX9708043A 1995-04-18 1996-04-18 Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior. MX9708043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/423,703 US5612027A (en) 1995-04-18 1995-04-18 Controlled release of miotic and mydriatic drugs in the anterior chamber
PCT/US1996/005395 WO1996032951A1 (en) 1995-04-18 1996-04-18 Controlled release of miotic and mydriatic drugs in the anterior chamber

Publications (1)

Publication Number Publication Date
MX9708043A true MX9708043A (es) 1998-03-31

Family

ID=23679887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708043A MX9708043A (es) 1995-04-18 1996-04-18 Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.

Country Status (26)

Country Link
US (4) US5612027A (es)
EP (1) EP0822822A4 (es)
JP (1) JP3314085B2 (es)
KR (1) KR100307685B1 (es)
CN (1) CN1181703A (es)
AP (1) AP850A (es)
AU (1) AU707013B2 (es)
BG (1) BG62598B1 (es)
BR (1) BR9608441A (es)
CA (1) CA2216417C (es)
CZ (1) CZ326497A3 (es)
DE (1) DE822822T1 (es)
EA (1) EA000790B1 (es)
EE (1) EE9700286A (es)
ES (1) ES2116950T1 (es)
GE (1) GEP20002231B (es)
HU (1) HUP9802665A3 (es)
IS (1) IS4572A (es)
MX (1) MX9708043A (es)
NO (1) NO974808L (es)
NZ (1) NZ306875A (es)
OA (1) OA10744A (es)
PL (1) PL322820A1 (es)
SK (1) SK140297A3 (es)
TR (1) TR199701192T1 (es)
WO (1) WO1996032951A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
WO1999055304A1 (en) 1998-04-29 1999-11-04 Novartis Ag Methods and compositions for stabilizing acetylcholine compositions
DK172900B1 (da) 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
EP1165097B1 (en) 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and their use
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US7879824B2 (en) * 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US20030060447A1 (en) * 2002-04-24 2003-03-27 Mutlu Karakelle Non-aspirating transitional viscoelastics for use in surgery
US7060297B2 (en) 2000-11-06 2006-06-13 Alcon, Inc. Carrageenan viscoelastics for ocular surgery
WO2002060486A2 (en) * 2001-01-29 2002-08-08 Fresco Bernard B Controlled release microsphere system for administration of drug to the eye
AU2002360939A1 (en) * 2001-11-21 2003-06-10 Novartis Ag Composition for stabilizing hyaluronic acid
CN101327325A (zh) 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
JP2004143155A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 眼科用剤
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2010115081A2 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Hair-like shaped hydrogels for soft tissue augmentation
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
PT3500255T (pt) 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
PL3681500T3 (pl) 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4303637A (en) * 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
FR2553099B1 (fr) * 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5093126A (en) * 1987-09-26 1992-03-03 Alcon Laboratories, Inc. Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
US4965253A (en) * 1987-10-14 1990-10-23 University Of Florida Viscoelastic material for ophthalmic surgery
US4920104A (en) * 1988-05-16 1990-04-24 Medchem Products, Inc. Sodium hyaluronate composition
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5007913A (en) * 1989-09-19 1991-04-16 Alcon Surgical, Inc. Apparatus and method for implantation of intraocular lenses
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
SE9301422D0 (sv) 1993-04-28 1993-04-28 Kabi Pharmacia Ab Method and means for inhibiting posterior capsule opacification
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber

Also Published As

Publication number Publication date
EA000790B1 (ru) 2000-04-24
WO1996032951A1 (en) 1996-10-24
KR100307685B1 (ko) 2001-12-12
IS4572A (is) 1997-09-30
US5612027A (en) 1997-03-18
CA2216417A1 (en) 1996-10-24
EE9700286A (et) 1998-06-15
BG101960A (en) 1998-04-30
CZ326497A3 (cs) 1998-09-16
NO974808D0 (no) 1997-10-17
PL322820A1 (en) 1998-02-16
HUP9802665A2 (en) 1999-06-28
ES2116950T1 (es) 1998-08-01
AP9701099A0 (en) 1997-10-31
DE822822T1 (de) 1998-09-03
US5965152A (en) 1999-10-12
BG62598B1 (bg) 2000-03-31
NO974808L (no) 1997-12-15
SK140297A3 (en) 1999-01-11
US5766580A (en) 1998-06-16
JPH10510293A (ja) 1998-10-06
TR199701192T1 (xx) 1998-02-21
BR9608441A (pt) 1999-02-17
CN1181703A (zh) 1998-05-13
KR19990007837A (ko) 1999-01-25
OA10744A (en) 2002-12-11
EP0822822A4 (en) 2006-01-11
AU5555796A (en) 1996-11-07
HUP9802665A3 (en) 2000-06-28
NZ306875A (en) 1999-06-29
CA2216417C (en) 2003-03-18
AU707013B2 (en) 1999-07-01
GEP20002231B (en) 2000-09-25
AP850A (en) 2000-06-14
EP0822822A1 (en) 1998-02-11
EA199700286A1 (ru) 1998-04-30
JP3314085B2 (ja) 2002-08-12
US5759532A (en) 1998-06-02

Similar Documents

Publication Publication Date Title
MX9708043A (es) Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.
AP9901655A0 (en) Controlled release of pharmaceuticals in the anterior chamber of the eye.
EP0705095B1 (en) Combinations of viscoelastics for use during surgery
US6107347A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
EP1263363B1 (en) Colored visco-elastic composition
JP2005523928A5 (es)
ITMI952744A1 (it) Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
Green Mussel adhesive protein
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
HK1045645A1 (zh) 消除角膜瘢痕、浑浊化和混浊的生化方法
Billowria et al. Topical advances in mucoadhesive ocular drug delivery system
JP3751017B2 (ja) 二頂分子量ヒアルロネート製剤およびその使用方法
Hollands et al. The effect of intracameral carbachol on intraocular pressure after cataract extraction
Ozerdem et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
EP0603112A1 (de) Verwendung von Thrombin-Inhibitoren zur Inhibition okularer Fibrinbildung
Madaan Developing implants for ophthalmic drug delivery and flow modulation
Cywiński Evaluation of Heavy Silicon Oil in the Treatment of Retinal Detachment Mainly Iinvolving Lower Quadrants
Machemer One of the most exciting developments in ophthalmology is taking place in an area that formerly received little attention. For years, most surgeons dreaded the disasters likely to occur after initially successful retinal surgery. It is only over the last 10 years or so that the problem of
Fisher et al. Microsurgical Management of Macular Epiretinal
RU94028870A (ru) Способ лечения посттравматической глаукомы
JPWO1999026637A1 (ja) 眼科用剤及び眼科用組成物